Severe hypoglycemia induced by Tigecycline in a diabetic and hemodialysis patient.

IF 1.4 4区 医学 Q4 INFECTIOUS DISEASES
Entela Puca, Edmond Puca, Klei Vrekaj, Dea Puca
{"title":"Severe hypoglycemia induced by Tigecycline in a diabetic and hemodialysis patient.","authors":"Entela Puca, Edmond Puca, Klei Vrekaj, Dea Puca","doi":"10.3855/jidc.18229","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tigecycline has a broad spectrum of activity, including activity against drug-resistant Gram-positive and -negative microorganisms. Its side effects are significant, but hypoglycemia is a rare finding during treatment. We aim to present an event of severe hypoglycemia in a patient with type 2 diabetes mellitus with replacement renal therapy, and hemodialysis after initiating tigecycline.</p><p><strong>Case presentation: </strong>A 54-year-old female diagnosed with type 2 diabetes mellitus was under treatment with basal-bolus insulin therapy and oral antihypertensive drugs. She started hemodialysis 24 months ago. She complained of recurrent fever for the last seven months and was treated with several antibiotics. In two separate blood cultures, she tested positive for methicillin-resistant Staphylococcus epidermidis (MRSE). Based on the antibiogram, we started treatment with tigecycline 100 mg/day. After 6-8 hours from the first dose, the patient is complicated with events of hypoglycemia and then continues with severe hypoglycemia (40-47 mg/dL). The patient continued to have hypoglycemia for about 16-18 hours after the last dose. We didn't find any reasons to explain the cause of episodes of hypoglycemia. She did not have high blood insulin levels (insulin 4.11 mIU/L [range 2.6-24.9]). We followed her for six months and the patient did not experience episodes of hypoglycemia.</p><p><strong>Conclusions: </strong>The association of severe hypoglycemia with tigecycline treatment is a very rare event and published papers on this topic are limited. Clinicians should be aware of this rare event when administering tigecycline and should routinely check blood glucose level during the treatment.</p>","PeriodicalId":49160,"journal":{"name":"Journal of Infection in Developing Countries","volume":"18 7","pages":"1157-1160"},"PeriodicalIF":1.4000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection in Developing Countries","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3855/jidc.18229","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Tigecycline has a broad spectrum of activity, including activity against drug-resistant Gram-positive and -negative microorganisms. Its side effects are significant, but hypoglycemia is a rare finding during treatment. We aim to present an event of severe hypoglycemia in a patient with type 2 diabetes mellitus with replacement renal therapy, and hemodialysis after initiating tigecycline.

Case presentation: A 54-year-old female diagnosed with type 2 diabetes mellitus was under treatment with basal-bolus insulin therapy and oral antihypertensive drugs. She started hemodialysis 24 months ago. She complained of recurrent fever for the last seven months and was treated with several antibiotics. In two separate blood cultures, she tested positive for methicillin-resistant Staphylococcus epidermidis (MRSE). Based on the antibiogram, we started treatment with tigecycline 100 mg/day. After 6-8 hours from the first dose, the patient is complicated with events of hypoglycemia and then continues with severe hypoglycemia (40-47 mg/dL). The patient continued to have hypoglycemia for about 16-18 hours after the last dose. We didn't find any reasons to explain the cause of episodes of hypoglycemia. She did not have high blood insulin levels (insulin 4.11 mIU/L [range 2.6-24.9]). We followed her for six months and the patient did not experience episodes of hypoglycemia.

Conclusions: The association of severe hypoglycemia with tigecycline treatment is a very rare event and published papers on this topic are limited. Clinicians should be aware of this rare event when administering tigecycline and should routinely check blood glucose level during the treatment.

一名糖尿病和血液透析患者因替加环素引发严重低血糖。
简介替加环素具有广泛的活性,包括对耐药性革兰氏阳性和阴性微生物的活性。其副作用很大,但在治疗过程中出现低血糖却很少见。我们旨在介绍一名 2 型糖尿病患者在接受替加环素治疗和血液透析后出现严重低血糖的病例:一名 54 岁的女性患者被诊断为 2 型糖尿病,接受基础胰岛素和口服降压药治疗。24 个月前,她开始进行血液透析。在过去的七个月中,她一直抱怨反复发烧,并接受了多种抗生素治疗。在两次不同的血液培养中,她的耐甲氧西林表皮葡萄球菌(MRSE)检测呈阳性。根据抗生素图谱,我们开始使用替加环素 100 毫克/天进行治疗。首次用药 6-8 小时后,患者出现复杂的低血糖症状,随后持续严重低血糖(40-47 毫克/分升)。最后一次用药后,患者持续低血糖约 16-18 小时。我们没有找到任何原因来解释低血糖发作的原因。她的血胰岛素水平并不高(胰岛素 4.11 mIU/L [范围 2.6-24.9])。我们对她进行了六个月的随访,患者没有再出现低血糖:结论:严重低血糖与替加环素治疗有关的情况非常罕见,已发表的相关论文也非常有限。临床医生在使用替加环素时应注意这种罕见情况,并在治疗期间定期检查血糖水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
5.30%
发文量
239
审稿时长
4-8 weeks
期刊介绍: The Journal of Infection in Developing Countries (JIDC) is an international journal, intended for the publication of scientific articles from Developing Countries by scientists from Developing Countries. JIDC is an independent, on-line publication with an international editorial board. JIDC is open access with no cost to view or download articles and reasonable cost for publication of research artcles, making JIDC easily availiable to scientists from resource restricted regions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信